Enhabit, Inc. (NYSE:EHAB) Given Average Recommendation of “Reduce” by Analysts

Shares of Enhabit, Inc. (NYSE:EHAB) have been assigned an average recommendation of “Reduce” from the seven brokerages that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $12.08.

Several research firms have recently weighed in on EHAB. UBS Group raised shares of Enhabit from a “sell” rating to a “neutral” rating and set a $9.50 target price on the stock in a report on Thursday, March 7th. Oppenheimer reaffirmed a “market perform” rating on shares of Enhabit in a research note on Thursday, March 7th. Finally, Jefferies Financial Group cut their target price on shares of Enhabit from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Wednesday, March 6th.

Enhabit Trading Down 0.8 %

Shares of Enhabit stock opened at $10.16 on Thursday. Enhabit has a 1 year low of $7.12 and a 1 year high of $14.59. The company has a market cap of $509.58 million, a price-to-earnings ratio of -6.27, a PEG ratio of 1.60 and a beta of 1.96. The company’s fifty day simple moving average is $10.15 and its 200-day simple moving average is $9.86. The company has a current ratio of 1.53, a quick ratio of 1.53 and a debt-to-equity ratio of 0.76.

Enhabit (NYSE:EHAB) last announced its quarterly earnings results on Wednesday, March 6th. The company reported $0.03 EPS for the quarter, beating the consensus estimate of $0.02 by $0.01. Enhabit had a positive return on equity of 1.55% and a negative net margin of 7.69%. The business had revenue of $260.60 million for the quarter, compared to analyst estimates of $260.30 million. During the same quarter in the previous year, the firm earned $0.32 EPS. As a group, sell-side analysts expect that Enhabit will post 0.24 EPS for the current year.

Hedge Funds Weigh In On Enhabit

A number of institutional investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in shares of Enhabit in the third quarter valued at approximately $97,492,000. Vanguard Group Inc. bought a new stake in shares of Enhabit during the third quarter worth $77,886,000. JANA Partners Management LP acquired a new position in shares of Enhabit during the third quarter valued at $20,532,000. State Street Corp bought a new stake in Enhabit during the third quarter worth about $22,827,000. Finally, UBS Group AG grew its stake in Enhabit by 7,973.5% in the third quarter. UBS Group AG now owns 1,633,751 shares of the company’s stock valued at $18,380,000 after purchasing an additional 1,613,515 shares in the last quarter.

About Enhabit

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.